Equibles does not estimate personal net worth.
Get an email with a short summary when BridgeBio Pharma, Inc. publishes a filing, an earnings call transcript or a press release.
Get BBIO alertsJustin Toews is recorded as CEO at BridgeBio Pharma, Inc. (BBIO). Justin Toews has spoken on 2 earnings calls and 1 other investor event across 1 company, most recently for BridgeBio Pharma, Inc. on February 24, 2026. BridgeBio Pharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BridgeBio Pharma, Inc. includes Neil Kumar (CEO and Board Member), Charles Homcy (Chairman and Board Member), Brian Stephenson (CFO) and 7 others.
“So infagratinib is the first oral therapeutic option for the treatment of achondroplasia. And more importantly, it's the first targeted treatment for achondroplasia.”
“Yeah, and for granted, just as a reminder, when we started this program, we had two key criteria, right? The first was to have a daily oral treatment option for families, and the second is to have deeper levels of efficacy by not only hitting the MAP-K pathway, but also STAT-1.”
Biotechnology · Healthcare
CEO
